Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IV Fexuprazan (DWJ1521) in Healthy Volunteers
NCT04827472Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fexuprazan in gastroesophageal reflux disease (GERD) (6 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Ratio of the time remaining above pH 4 and pH 6. Status: unknown.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04827472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827472.